How research, product development and hiring are changing in Women's Health

Investors, policymakers and pharmaceutical companies are giving women’s health more attention. This matters, but funding and policy support alone do not put a treatment into clinical practice. Products still need sound evidence, clinician confidence and a workable route through reimbursement and routine care.  

For companies entering the field, the opportunity is broad: women’s health now covers menstruation, pregnancy, menopause and conditions that affect women differently from men. The strongest programmes, however, begin with a tightly defined clinical problem and a clear account of how the product will change care. 

The research and product picture 

The research base is beginning to catch up with that ambition. In 2024, the US National Institutes of Health committed $200 million to an agency-wide programme addressing gaps in women’s health research across the lifespan, including the effects of menopause on heart, brain and bone health. 

At the same time, menopause has become a serious area of drug development. Bayer’s elinzanetant received its first approval in the UK in July 2025, followed by approvals in the US and European Union later that year, giving clinicians another non-hormonal treatment for hot flushes and night sweats. 

Bayer’s progress shows what sustained development and regulatory work can achieve in a market that has often been treated as secondary. Organon remains one of the few global pharmaceutical companies organised around women’s health; growth in parts of its fertility business during 2025 was encouraging, although weaker results elsewhere in the portfolio showed why it still needs new products. 

Around these larger companies, specialist biotechnology and diagnostics businesses are working on endometriosis, maternal health, reproductive medicine and ovarian cancer detection. There is no single platform leading the field. Progress is coming through medicines, diagnostics and care tools built for specific clinical uses. 

Where investment is moving 

That specificity is becoming more important as investment spreads beyond contraception and fertility. Endometriosis, polycystic ovary syndrome, uterine fibroids and maternal health all involve large patient populations, long waits for diagnosis and fragmented care. Those gaps create room for better tests, treatments and referral pathways, but awareness on its own is not enough. Patient communities can support recruitment and help explain poorly recognised conditions; prescribing and reimbursement still depend on validated endpoints, defensible claims and evidence that fits the decisions clinicians and payers make. 

The same discipline applies to financing. A company has a stronger case when it can describe the benefit in practical terms: an earlier diagnosis, fewer invasive procedures, a better chance of pregnancy or relief from severe symptoms. Market size carries less weight without a clear view of who will use the product and where it fits in care. 

Some investment is therefore going into the foundations of better research, including representative datasets, decentralised trials, sex-specific analysis and digital outcome measures. These capabilities can widen recruitment and produce evidence that regulators and payers can assess. 

What this means for leadership 

The hiring market reflects this shift from broad promise to product execution. Demand is strongest for medical and development leaders who know the relevant patient group and clinical setting. Menopause experience is different from reproductive endocrinology, obstetrics, endometriosis or maternal health, so companies need to be precise about the knowledge the role requires.  

Clinical operations leaders must make participation workable without weakening the science. Regulatory and evidence specialists need to choose acceptable endpoints and validate diagnostic tools properly, while market access and health economics leaders must show which costs a product could reduce, whose budget is affected and what evidence the buyer will expect. Commercial leadership also matters early where diagnosis is inconsistent or clinical awareness is low. 

Senior searches become difficult when every preference is treated as essential: the same therapeutic area, product type, company stage, milestone and location. Some criteria will be non-negotiable; others may describe the previous role holder rather than the work ahead. A candidate may be new to the exact indication but have led the regulatory submission, financing or launch the company now faces. That experience can be more useful than a close therapeutic match without a comparable operating record. 

Experienced candidates will also examine the science, cash runway, board and decision-making structure before moving. Pay matters, as does authority. A senior title carries little weight if the main decisions sit elsewhere, so candidates will want to know which choices they will own and whether the team has the resources to carry them through. 

What companies should do now 

For biotech companies, the practical work starts early. Define the patients, the clinical decision that needs to change and the outcome the product is intended to improve. Use patient experience to shape endpoints, recruitment, adherence and product design. 

Identify the payer, the relevant budget and the evidence required for coverage while the product is still in development. Medical, economic and commercial questions should be considered together, with finance, regulatory, data and commercial leaders each given clear responsibility for the programme’s route into care. 

More money is entering women’s health, but the standard for success is familiar: convincing trial results, regulatory approval, reimbursement and regular use by clinicians. Specialist knowledge of women’s health is most useful when it is joined to strong development, regulatory and commercial judgement. 

When assessing a senior hire, companies should look at the decisions that person will own over the next 18 months and ask what they have led themselves, where plans have failed and what they changed afterwards. The most familiar CV will not always be the best preparation for the next milestone.